STOCK TITAN

Abbott Laboratories - ABT STOCK NEWS

Welcome to our dedicated page for Abbott Laboratories news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Laboratories stock.

Abbott Laboratories (NYSE: ABT) is a globally recognized American multinational company headquartered in Abbott Park, Illinois. Founded in 1888, Abbott has established itself as a leader in medical devices and health care. The company manufactures and markets a wide range of products, including cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment, testing kits, and branded generic drugs.

Abbott's product portfolio includes pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays along with point-of-care diagnostic equipment. Approximately 60% of Abbott’s sales are derived from markets outside the United States, underlining its global reach and influence.

Recently, Abbott introduced the PROTALITY™ brand, a high-protein nutrition shake aimed at supporting weight loss while preserving muscle mass. This innovation reflects Abbott's commitment to addressing global health challenges such as obesity and muscle health. The company also continues to make strides in medical technology with advancements like the TriClip™ system for tricuspid valve repair, and the FreeStyle Libre continuous glucose monitoring systems, which have set new standards in diabetes management.

Abbott is not only focused on innovative product development but also on strategic partnerships and sustainability. The extension of their partnership with the Real Madrid Foundation, aimed at reducing childhood malnutrition and promoting healthy habits, is a testament to their commitment to global health improvements.

Financially, Abbott has demonstrated robust performance, as evidenced by its consistent dividend payouts and its inclusion in the S&P 500 Dividend Aristocrats Index. The company reported strong Q1 2024 results with significant growth in their core business segments, further supported by successful product launches and clinical innovations.

Abbott’s mission to help people live more fully at all stages of life drives their development of life-changing technologies across diagnostics, medical devices, nutritionals, and branded generic medicines. With a workforce of over 114,000 employees serving people in over 160 countries, Abbott continues to set benchmarks in the healthcare industry.

Rhea-AI Summary
Abbott (NYSE: ABT) has launched its new PROTALITY™ brand, offering a high-protein nutrition shake to support weight loss while preserving muscle mass. The brand is aimed at adults pursuing weight loss, with the first product featuring 30 grams of protein, essential B vitamins, comfort fiber, and 150 calories. The shake is now available online and at various retailers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
none
-
Rhea-AI Summary
Abbott (NYSE: ABT) has received FDA approval for the Liberta RC™ deep brain stimulation (DBS) system, the world's smallest rechargeable DBS device with remote programming. It offers the longest time between charges of any DBS technology on the market, requiring only 10 recharge sessions a year for most people. The system features NeuroSphere™ Virtual Clinic, allowing remote communication with doctors, ensuring proper settings and functionality, and receiving new treatment settings without visiting a doctor's office.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
none
-
Rhea-AI Summary
Abbott announced fourth-quarter sales increase of 1.5 percent, full-year 2023 reported sales decreased by 8.1 percent due to COVID-19 testing-related sales; organic sales growth increased by 11.6 percent. The company projects full-year 2024 organic sales growth to be in the range of 8.0% to 10.0%. The R&D pipeline continues to deliver new products, and the company has regained its market-leading position in the U.S. infant formula market. Abbott's new laboratory automation system, GLP systems Track™, received FDA approval, and the company's Volt™ Pulsed Field Ablation System was used for the first time in humans. Abbott's Tandem Diabetes Care's t:slim X2™ insulin pump is now the first automated insulin delivery system in the U.S. to integrate with Abbott's new FreeStyle Libre® 2 Plus sensor. The company's EPS was $3.26 for full-year 2023 and projects a diluted EPS on a GAAP basis of $3.20 to $3.40 for full-year 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
Rhea-AI Summary
Abbott has earned the top overall industry score for 11 years and leads in health access on the global sustainability benchmark DJSI. The company's 2030 Sustainability Plan aims to improve the health of 3 billion people annually by 2030, with a focus on connecting care and technology to put people in control. Abbott also achieved top scores in key social, environmental, and governance categories on the S&P Global Corporate Sustainability Assessment, confirming its position as a leader in sustainability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
none
-
Rhea-AI Summary
Abbott (ABT) announces the first global procedures using the Volt Pulsed Field Ablation (PFA) System to treat patients with atrial fibrillation. The system uses high energy electrical pulses to destroy cells causing abnormal heart rhythms, reducing the risk of damaging adjacent tissue. The Volt PFA System is designed to overcome limitations of first-generation PFA systems and provide a more accurate and efficient workflow for physicians.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
-
Rhea-AI Summary
Abbott (ABT) and Tandem Diabetes Care (TNDM) have announced the integration of the FreeStyle Libre 2 Plus sensor with the t:slim X2 insulin pump in the U.S. This marks the first time that Tandem's Control-IQ technology is compatible with the 15-day continuous glucose monitoring (CGM) sensor, providing a hybrid closed-loop system for users in the United States.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
none
Rhea-AI Summary
Abbott (NYSE: ABT) is set to announce its fourth-quarter 2023 financial results on January 24, 2024, before the market opens. The live webcast of the earnings conference call will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
-
Rhea-AI Summary
Abbott (NYSE: ABT) to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
conferences
-
Rhea-AI Summary
Abbott (NYSE: ABT) increases its quarterly common dividend by 7.8% to 55 cents per share, marking 52 years of consecutive dividend growth. The company will pay its 400th consecutive quarterly dividend since 1924 on Feb. 15, 2024. Abbott is a member of the S&P 500 Dividend Aristocrats Index, demonstrating its commitment to delivering strong shareholder returns and top-tier growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
dividends
Rhea-AI Summary
Surmodics, Inc. (NASDAQ:SRDX) announced the 36-month data from its TRANSCEND clinical trial, presenting the safety and efficacy of the SurVeil drug coated balloon (DCB) compared to the IN.PACT Admiral DCB for treating superficial femoral and proximal popliteal artery lesions. The primary efficacy and safety endpoints showed comparable outcomes, demonstrating the non-inferiority of the SurVeil DCB to the IN.PACT Admiral DCB. Dr. Peter A. Schneider presented the data at the 50th Annual VEITH Symposium in New York, New York.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
none

FAQ

What is the current stock price of Abbott Laboratories (ABT)?

The current stock price of Abbott Laboratories (ABT) is $114.23 as of December 20, 2024.

What is the market cap of Abbott Laboratories (ABT)?

The market cap of Abbott Laboratories (ABT) is approximately 196.0B.

What does Abbott Laboratories specialize in?

Abbott Laboratories specializes in cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment, testing kits, and branded generic drugs.

What are some of Abbott’s recent product launches?

Recent product launches include the PROTALITY™ high-protein nutrition shake and the TriClip™ system for tricuspid valve repair.

How much of Abbott’s sales are generated outside the United States?

Approximately 60% of Abbott’s sales are generated outside the United States.

What is Abbott’s PROTALITY™ brand?

The PROTALITY™ brand is a high-protein nutrition shake designed to support weight loss while preserving muscle mass, addressing global health challenges like obesity.

How does Abbott support global health initiatives?

Abbott supports global health initiatives through strategic partnerships like their collaboration with the Real Madrid Foundation to reduce childhood malnutrition and promote healthy habits.

What is Abbott’s financial performance like?

Abbott has demonstrated robust financial performance, with strong Q1 2024 results and a consistent track record of dividend payouts, evidenced by its inclusion in the S&P 500 Dividend Aristocrats Index.

How many employees does Abbott have?

Abbott employs over 114,000 people worldwide.

Which continuous glucose monitoring system is Abbott known for?

Abbott is known for its FreeStyle Libre continuous glucose monitoring systems, which are widely recognized for their innovation in diabetes management.

What is Abbott's mission?

Abbott's mission is to help people live more fully at all stages of life by developing life-changing technologies spanning diagnostics, medical devices, nutritionals, and branded generic medicines.

In how many countries does Abbott operate?

Abbott operates in more than 160 countries worldwide.

Abbott Laboratories

NYSE:ABT

ABT Rankings

ABT Stock Data

196.01B
1.72B
0.53%
77.7%
0.69%
Medical Devices
Pharmaceutical Preparations
Link
United States of America
ABBOTT PARK